News

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.

Net profit of Alivus Life Sciences rose 14.65% to Rs 162.66 crore in the quarter ended March 2026 as against Rs 141.87 crore during the previous quarter ended March 2025. Sales rose 6.09% to Rs 689.12 crore in the quarter ended March 2026 as against Rs 649.55 crore during the previous quarter ended March 2025.For the full year,net profit rose 16.24% to Rs 564.48 crore in the year ended March 2026 as against Rs 485.63 crore during the previous year ended March 2025. Sales rose 6.91% to Rs 2551.83 crore in the year ended March 2026 as against Rs 2386.88 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales689.12649.55 6 2551.832386.88 7 OPM %31.1330.55 -31.2428.60 - PBDT236.00207.27 14 852.32714.74 19 PBT215.80191.30 13 776.96654.13 19 NP162.66141.87 15 564.48485.63 16 Powered by Capital Market - Live News

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Net profit of Alivus Life Sciences rose 9.71% to Rs 150.26 crore in the quarter ended December 2025 as against Rs 136.96 crore during the previous quarter ended December 2024. Sales rose 4.84% to Rs 672.89 crore in the quarter ended December 2025 as against Rs 641.84 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales672.89641.84 5 OPM %34.3729.65 - PBDT243.71200.31 22 PBT224.05185.15 21 NP150.26136.96 10 Powered by Capital Market - Live News

Alivus Life Sciences has allotted 55,000 equity shares under ESOS on 21 January 2026. With this allotment, the paid up equity share capital has increased to 12,27,36,348 equity shares of Rs. 2 each aggregating to Rs. 24,54,72,696/-. Powered by Capital Market - Live News